An observational study in Cataract, sponsored by Aloha Vision Consultants. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-10-09.
Sponsored by Aloha Vision Consultants · Observational
This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.
1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's planned enrollment of 50 is below the median of 81 across 484 observational studies indexed under Cataract.
Browse Cataract studies →This is the only study on the registry with Aloha Vision Consultants as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Eligible test subjects will be adults who are candidates for age-related cataract surgery with IOL implantation.
Exclusion Criteria:
Veritas Vision System
Effective phaco time per phacoemulsification procedure
Time frame: Surgery (Day 0)
Endothelial cell loss
Time frame: 1 monthspostoperatively
Total case time
total case time per procedure
Time frame: Surgery (Day 0)
Total phaco time
total phaco time per procedure
Time frame: Surgery (Day 0)
Total volume used
Total volume used per procedure
Time frame: Surgery (Day 0)
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.